277 related articles for article (PubMed ID: 29089584)
21. Long-term Musculoskeletal Consequences of Chemotherapy in Pediatric Mice.
Huot JR; Livingston PD; Pin F; Thomas CR; Jamnick NA; Callaway CS; Bonetto A
Function (Oxf); 2024; 5(3):zqae011. PubMed ID: 38706958
[TBL] [Abstract][Full Text] [Related]
22. Dietary calcium intake and genetics have site-specific effects on peak trabecular bone mass and microarchitecture in male mice.
Chanpaisaeng K; Reyes Fernandez PC; Fleet JC
Bone; 2019 Aug; 125():46-53. PubMed ID: 31078711
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.
Kim JW; Lee KW; Kim KP; Lee JH; Hong YS; Kim JE; Kim SY; Park SR; Nam BH; Cho SH; Chung IJ; Park YS; Oh HS; Lee MA; Kang HJ; Park YI; Song EK; Han HS; Lee KT; Shin DB; Kang JH; Zang DY; Kim JH; Kim TW
Oncologist; 2017 Mar; 22(3):293-303. PubMed ID: 28209749
[TBL] [Abstract][Full Text] [Related]
24. Differential Bone Loss in Mouse Models of Colon Cancer Cachexia.
Bonetto A; Kays JK; Parker VA; Matthews RR; Barreto R; Puppa MJ; Kang KS; Carson JA; Guise TA; Mohammad KS; Robling AG; Couch ME; Koniaris LG; Zimmers TA
Front Physiol; 2016; 7():679. PubMed ID: 28123369
[TBL] [Abstract][Full Text] [Related]
25. Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats.
Ke HZ; Qi H; Chidsey-Frink KL; Crawford DT; Thompson DD
J Bone Miner Res; 2001 Apr; 16(4):765-73. PubMed ID: 11316005
[TBL] [Abstract][Full Text] [Related]
26. Mapping quantitative trait loci for vertebral trabecular bone volume fraction and microarchitecture in mice.
Bouxsein ML; Uchiyama T; Rosen CJ; Shultz KL; Donahue LR; Turner CH; Sen S; Churchill GA; Müller R; Beamer WG
J Bone Miner Res; 2004 Apr; 19(4):587-99. PubMed ID: 15005846
[TBL] [Abstract][Full Text] [Related]
27. A novel flavonoid C-glucoside from Ulmus wallichiana preserves bone mineral density, microarchitecture and biomechanical properties in the presence of glucocorticoid by promoting osteoblast survival: a comparative study with human parathyroid hormone.
Khan MP; Mishra JS; Sharan K; Yadav M; Singh AK; Srivastava A; Kumar S; Bhaduaria S; Maurya R; Sanyal S; Chattopadhyay N
Phytomedicine; 2013 Nov; 20(14):1256-66. PubMed ID: 23928508
[TBL] [Abstract][Full Text] [Related]
28. Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse.
Misof BM; Roschger P; Baldini T; Raggio CL; Zraick V; Root L; Boskey AL; Klaushofer K; Fratzl P; Camacho NP
Bone; 2005 Jan; 36(1):150-8. PubMed ID: 15664013
[TBL] [Abstract][Full Text] [Related]
29. Renin inhibitor aliskiren exerts beneficial effect on trabecular bone by regulating skeletal renin-angiotensin system and kallikrein-kinin system in ovariectomized mice.
Zhang Y; Wang L; Song Y; Zhao X; Wong MS; Zhang W
Osteoporos Int; 2016 Mar; 27(3):1083-1092. PubMed ID: 26439241
[TBL] [Abstract][Full Text] [Related]
30. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
[TBL] [Abstract][Full Text] [Related]
31. Preventive effects of berberine on glucocorticoid-induced osteoporosis in rats.
Xu D; Yang W; Zhou C; Liu Y; Xu B
Planta Med; 2010 Nov; 76(16):1809-13. PubMed ID: 20577944
[TBL] [Abstract][Full Text] [Related]
32. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
[TBL] [Abstract][Full Text] [Related]
33. Estrogen Deficiency-Associated Bone Loss in the Maxilla: A Methodology to Quantify the Changes in the Maxillary Intra-radicular Alveolar Bone in an Ovariectomized Rat Osteoporosis Model.
Du Z; Steck R; Doan N; Woodruff MA; Ivanovski S; Xiao Y
Tissue Eng Part C Methods; 2015 May; 21(5):458-66. PubMed ID: 25315176
[TBL] [Abstract][Full Text] [Related]
34. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
Meng Y; Zhang H; Li Y; Li Q; Zuo L
Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
[TBL] [Abstract][Full Text] [Related]
35. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
36. Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity.
Sato M; Westmore M; Ma YL; Schmidt A; Zeng QQ; Glass EV; Vahle J; Brommage R; Jerome CP; Turner CH
J Bone Miner Res; 2004 Apr; 19(4):623-9. PubMed ID: 15005850
[TBL] [Abstract][Full Text] [Related]
37. [Second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer after resection of the primary lesion].
Abe H; Mafune K; Minamimura K; Abe M; Umemura A; Hirata T
Gan To Kagaku Ryoho; 2013 May; 40(5):601-4. PubMed ID: 23863581
[TBL] [Abstract][Full Text] [Related]
38. Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer.
Folprecht G; Tabernero J; Köhne CH; Zacharchuk C; Paz-Ares L; Rojo F; Quinn S; Casado E; Salazar R; Abbas R; Lejeune C; Marimón I; Andreu J; Ubbelohde U; Cortes-Funes H; Baselga J
Clin Cancer Res; 2008 Jan; 14(1):215-23. PubMed ID: 18172273
[TBL] [Abstract][Full Text] [Related]
39. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
[TBL] [Abstract][Full Text] [Related]
40. Lack of α2C-Adrenoceptor Results in Contrasting Phenotypes of Long Bones and Vertebra and Prevents the Thyrotoxicosis-Induced Osteopenia.
Cruz Grecco Teixeira MB; Martins GM; Miranda-Rodrigues M; De Araújo IF; Oliveira R; Brum PC; Azevedo Gouveia CH
PLoS One; 2016; 11(1):e0146795. PubMed ID: 26815679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
